Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR) T cell therapy has shown limited success in solid tumors, mainly because of the scarcity of tumor‐specific surface antigens. To address this challenge, we developed an integrated computational and experimental pipeline for antigen discovery and applied it to melanoma. Our bioinformatics strategy introduced a novel quantitative metric, the restrictiveness ratio , to identify antigens highly expressed in tumors but minimally present in healthy tissues. Using RNA‐sequencing data from patient samples, we compared candidate targets with the established melanoma antigen chondroitin sulphate proteoglycan 4 (CSPG4) and validated their expression on melanoma cell lines. CARs were engineered against selected antigens, CAR‐T cells were generated by RNA electroporation, and expression was confirmed. Functional validation included T cell activation, cytokine secretion, and cytotoxicity assays. RNA‐seq analysis of cutaneous and uveal melanoma identified 90 and 84 candidate genes, respectively, encoding transmembrane proteins with tumor expression above 10 TPM (transcripts per million). Fifty‐six genes displayed higher restrictiveness ratios than CSPG4. Following manual curation and scFv (single‐chain variable fragment) availability assessment, five candidates were prioritized. CARs targeting ErbB3 and SLC1A5 induced strong antigen‐specific T cell activation and cytotoxicity comparable to CSPG4‐CARs. These findings identify ErbB3 and SLC1A5 as promising CAR‐T targets and establish an integrative bioinformatics‐driven framework for extending CAR‐T therapy to solid tumors.
No takes yet. Share an insight, caveat, or question.
Juraschek et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: